Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

Stor kongress om framtidsutsikter igång i Lund

Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.

Avtal sluts mellan stora svenska och nederländska aktörer

Fyra överenskommelser mellan svenska och nederländska life science-aktörer ska skrivas idag. Avtalen signeras i samband med det pågående statsbesöket från Neder...

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease

According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration o...

Hon blir vice vd för Medicon Village

Medicon Village rekryterar från Medicon Valley Alliance.

EU bokar 40 miljoner doser fågelinfluensavaccin

EU säkrar 40 miljoner doser vaccin mot fågelinfluensa – redan innan smittan nått Europa.

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Lundabolag får brittiskt miljonbidrag för blodtest

Lundabolaget Prolight Diagnostics har fått ett statligt brittiskt bidrag på 17 miljoner kronor för fortsatt utveckling av ett blodtest som ska upptäcka eller ut...

Ready-to-install solutions for the lab-on-a-chip

Design for manufacturing lab-on-a-chip devices Reducing time-to-market together

Noxious parasite forms hybrids and deceives the immune system

The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to decei...

Nytt internationellt center för stamcellsforskning skapas i Köpenhamn

Ett nytt center för stamcellsforskning slår upp portarna i januari månad. Bakom satsningen står Novo Nordisk Foundation och förhoppningen är att centret ska led...

Missnöjd med din julklappsslips? Här är våra läsetips

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Ännu ett Alzheimerläkemedel godkänt – lecanemab får konkurrens

Eli Lillys läkemedel donanemab mot Alzheimers godkändes på tisdagen av den amerikanska läkemedelsmyndigheten FDA. Det är det andra godkända bromsläkemedlet mot ...

Så blir svenska paviljongen vid Bio-Europe

Jättekonferensen Bio-Europe med över 5 000 deltagare äger i år för första gången rum i Stockholm – och svensk life science samlar styrkorna.